UNSPSC 51391619: Ractopamine hydrochloride

This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 309G9J93TP, chemically known as benzenemethanol, 4-hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)- but more generally known as ractopamine hydrochloride, which bears US NIH Compound Identifier 56052. Most nations, for tariff and trade purposes, schedule ractopamine hydrochloride under HS 29225000 and SITC 51467.

As of Q4 2014, RACTOPAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ractopamine hydrochloride bears US NLM identifiers UMLS ID C0958044 and NCI Concept Code C84133. SMILES: CC(CCC1CCC(CC1)O)NCC(C2CCC(CC2)O)O.CL.

UNSPSC 51391619 Ractopamine hydrochloride is a Commodity code that nominally designates a specific pharmaceutical compound used as a feed additive in livestock production. However, recent state and local procurement activity tagged to this code shows no alignment with that scope. The two recent opportunities posted under this code — one from Seminole County, Florida soliciting naloxone and drug deactivation systems for community health, and one from the Texas Health and Human Services Commission conducting market research on direct-to-manufacturer prescription programs — involve neither ractopamine nor veterinary pharmaceuticals. This mismatch suggests either a cataloging error in how opportunities are tagged to the code or that the code's practical use in state and local procurement has drifted substantially from its nominal definition. Based on the available recent activity, the code shows little relevant procurement activity aligned with its stated commodity scope.

Geographic activity appears concentrated in Florida and Texas, though both opportunities represent exploratory or equipment-procurement work outside the code's nominal veterinary-pharmaceutical domain. Seminole County's IFB 60459723LAS (posted June 30, 2026, with response due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive-bid basis, with quarterly deliveries to the county's community health building and a two-year initial term plus one-year renewal option. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) is an exploratory market-intelligence solicitation on direct-to-manufacturer prescription distribution, not a formal competitive procurement. Absent recent opportunities that actually procure ractopamine or related livestock pharmaceuticals under this code, tracking activity here offers limited business-development signal for vendors in that market segment.